1056271-56-7

Upstream product

• 939437-05-5 diethyl N-[4-[[2-(2,4-diamino-5-(2,3-dibromopropane)-5,6,7,8-tetrahydropyrido[3,2-d]pyrimidin-6-yl)methyl]amino]3-bromo-benzoyl]-L-glutamate 
• 76822-61-2 2,4-Diamino-6-(hydroxymethyl)pyrido<3,2-d>pyrimidine 
• 13726-52-8 diethyl N-(p-aminobenzoyl)-L-glutamate 
• 1392197-17-9 2,4-diamino-5,6-methylene-5,6,7,8-tetrahydropyrido[3,2-d]pyrimidine 
• 1392197-19-1 2,4-diamino-6-chloromethyl-5,6,7,8-tetrahydropyrido[3,2-d]pyrimidine 
• 1392197-18-0 (2,4-diamino-5,6,7,8-tetrahydropyrido[3,2-d]pyrimidin-6-yl)methanol 
• 939436-99-4 diethyl N-[4-[[2-(2,4-diamino-5,6,7,8-tetrahydropyrido[3,2-d]pyrimidin-6-yl)methyl]amino]benzoyl]-L-glutamate 
• 939437-03-3 diethyl N-[4-[[2-(2,4-diamino-5-allyl-5,6,7,8-tetrahydropyrido[3,2-d]pyrimidin-6-yl)methyl]amino]benzoyl]-L-glutamate 

Relevant academic research and scientific papers

Novel Synthesis of 8-deaza-5,6,7,8-tetrahydroaminopterin analogues via an aziridine intermediate

An efficient method for the construction of the tetrahydrofolate skeleton is described. Starting from pterin analogues and aromatic amines, 8-deaza-5,6,7,8- tetrahydroaminopterin derivatives and the heterocyclic benzoyl isosteres were synthesized via a novel aziridine intermediate. Following this method, the byproducts of carbonnitrogen bond hydrogenolysis in traditional synthetic strategy can be completely avoided.

Novel 8-deaza-5,6,7,8-tetrahydroaminopterin derivatives as dihydrofolate inhibitor: Design, synthesis and antifolate activity

We report, for the first time, the synthesis and biological activities of 8-deaza-5,6,7,8-tetrahydroaminopterin 9, and the 5-substituted and 5,10-disubstituted analogues 11, 13, 15, and 17. The analogues were obtained from key compound diethyl 8-deaza-5,6,7,8-tetrahydroaminopterin 8 following the catalytic reduction of the pyridine ring of diethyl 8-deaza aminopterin 5. The five novel 8-deaza-5,6,7,8-tetrahydroaminopterin derivatives were assayed in vitro for their cytotoxicity on BGC-823, HL-60, Bel-7402 and Hela tumor cell lines, and inhibition on recombinant human dihydrofolate reductase (DHFR), among which the most potent molecule (compound 9) was about 4- to 10-fold poorer than MTX on the four kinds of tumor cell lines, and its effect on DHFR was about 17-fold poorer than MTX. The docking studies were followed to explain the biological testing results.